Wedbush Weighs in on Nuvation Bio's Q3 Earnings (NYSE:NUVB)

Nuvation Bio Inc. (NYSE:NUVB - Free Report) - Wedbush lifted their Q3 2025 earnings estimates for Nuvation Bio in a research report issued on Wednesday, May 7th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.18) per share for the quarter, up from their previous forecast of ($0.20). Wedbush has a "Outperform" rating and a $5.00 price objective on the stock. The consensus estimate for Nuvation Bio's current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Nuvation Bio's Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.41) EPS and FY2028 earnings at ($0.05) EPS.

NUVB has been the topic of several other reports. Jones Trading began coverage on shares of Nuvation Bio in a report on Wednesday, March 12th. They issued a "buy" rating and a $10.00 price target on the stock. HC Wainwright lowered their price target on shares of Nuvation Bio from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Monday, March 10th. Citizens Jmp assumed coverage on shares of Nuvation Bio in a research report on Wednesday, April 23rd. They issued a "mkt outperform" rating and a $6.00 target price for the company. Citigroup started coverage on shares of Nuvation Bio in a research report on Wednesday, April 23rd. They set an "outperform" rating for the company. Finally, JMP Securities started coverage on shares of Nuvation Bio in a research note on Wednesday, April 23rd. They set a "market outperform" rating and a $6.00 price objective for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $7.83.

Nuvation Bio Price Performance

NUVB traded down $0.01 during trading on Monday, hitting $2.24. The company had a trading volume of 405,227 shares, compared to its average volume of 2,202,892. The company has a market cap of $756.95 million, a PE ratio of -1.03 and a beta of 1.42. The business has a 50-day moving average of $2.01 and a 200-day moving average of $2.36. Nuvation Bio has a 1-year low of $1.54 and a 1-year high of $3.97.

Nuvation Bio (NYSE:NUVB - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). The company had revenue of $3.08 million during the quarter, compared to analyst estimates of $0.42 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its position in Nuvation Bio by 54.9% during the 4th quarter. FMR LLC now owns 45,285,572 shares of the company's stock worth $120,460,000 after buying an additional 16,046,701 shares in the last quarter. Vanguard Group Inc. lifted its position in Nuvation Bio by 45.4% during the 4th quarter. Vanguard Group Inc. now owns 15,732,567 shares of the company's stock worth $41,849,000 after buying an additional 4,913,820 shares in the last quarter. Geode Capital Management LLC lifted its position in Nuvation Bio by 22.9% during the 4th quarter. Geode Capital Management LLC now owns 4,951,195 shares of the company's stock worth $13,174,000 after buying an additional 922,503 shares in the last quarter. MPM Bioimpact LLC raised its holdings in Nuvation Bio by 11.7% during the 1st quarter. MPM Bioimpact LLC now owns 4,652,243 shares of the company's stock worth $8,188,000 after purchasing an additional 488,065 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in Nuvation Bio by 82.7% during the 4th quarter. Millennium Management LLC now owns 2,475,872 shares of the company's stock worth $6,586,000 after purchasing an additional 1,120,874 shares during the last quarter. Institutional investors and hedge funds own 61.67% of the company's stock.

Insider Buying and Selling

In other news, insider Dongfang Liu sold 20,000 shares of the business's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $2.50, for a total value of $50,000.00. Following the sale, the insider now owns 12,000 shares in the company, valued at approximately $30,000. The trade was a 62.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO David Hung bought 300,000 shares of Nuvation Bio stock in a transaction dated Monday, April 7th. The stock was purchased at an average price of $1.62 per share, for a total transaction of $486,000.00. Following the purchase, the chief executive officer now directly owns 58,781,054 shares in the company, valued at $95,225,307.48. This represents a 0.51% increase in their position. The disclosure for this purchase can be found here. 29.93% of the stock is currently owned by insiders.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.